Reportable segment disclosure

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Reportable segment disclosure

Note 16: Reportable segment disclosure

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Clinical studies	10,130	12,929	33,190	34,157
BLA & Regulatory	3,296	2,031	6,979	5,121
Medical Affairs & Other Medical	2,256	2,156	6,223	6,446
Research & Innovation	364	322	1,450	1,087
Manufacturing & Supply and Quality	12,569	6,224	35,948	23,627
Sales & Marketing	1,178	519	1,859	2,263
General & Administrative	7,259	7,220	21,348	23,667
Total expenses	37,051	31,401	106,997	96,368

The Company operates and is managed as one operating segment driving expenses for the development of the Viaskin Peanut patch. The Company’s R&D organization is primarily responsible for the development and registration efforts of the Viaskin Peanut patch. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product. The Company is also supported by corporate staff functions.

The Company’s Chief Executive Officer as the CODM manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.

The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Consolidated Statement of Financial Position with particular emphasis on the Company's available liquidity including cash, cash equivalents.